度伐利尤单抗联合曲美木单抗与图像引导立体定向体部放疗治疗转移性未分化甲状腺癌的初步研究
这项初步研究评估曲美木单抗联合度伐利尤单抗及立体定向体部放疗(SBRT)治疗转移性未分化甲状腺癌(ATC)的总生存(OS)。12例患者接受治疗,主要终点1年OS未达到目标,中位OS为14.5周,仅1例存活超过1年,无确认缓解。结论认为该联合方案未改善OS,需未来研究其他免疫联合方案。
要点
- 12例转移性ATC患者接受曲美木单抗、度伐利尤单抗联合SBRT,中位OS为14.5周。
- 零例确认缓解,仅1例疾病稳定并接受≥4周期研究药物。
- 仅有1例患者存活超过1年,未达到1年OS在12例中≥2例的目标。
核心结论
- 曲美木单抗联合度伐利尤单抗及SBRT未改善转移性ATC患者的总生存。
- 未来研究需要探索其他新型免疫联合方案联合或不联合放疗治疗ATC。
研究设计与样本
- 初步研究,纳入转移性ATC患者,计划入组12例,实际12例参与。
- 主要纳入标准:转移性ATC、ECOG体能状态0-2、无既往免疫治疗、末次抗癌治疗距研究开始>7天。
- 治疗方案:曲美木单抗75 mg每4周一次,最多4剂;度伐利尤单抗1500 mg每4周一次,最长1年;SBRT 9 Gy×3次,在治疗开始前2周内给予。
- 主要终点为1年OS,目标为12例中≥2例达到1年OS。
主要发现
- 共13例患者签署知情同意,最终12例参与;1例因体能状态持续下降不符合条件。
- 患者特征:男性6例,中位年龄71岁(范围49-82),ECOG=1;9例有颈部放疗史,9例有化疗史。
- 在9例有组织可用的患者中进行了二代测序和PD-L1染色,2例检测到高微卫星不稳定(MSI)对应错配修复缺陷。
- 零例确认缓解,仅1例疾病稳定并接受≥4周期研究药物;中位治疗时间为11周(范围1-28周)。
- MSI状态未影响治疗反应,高MSI患者治疗8-14周后疾病进展;中位OS为14.5周,仅1例存活超过1年;BRAF或p53突变存在似乎不影响治疗结果。
关键数值与推荐
- 主要终点1年OS目标为12例中≥2例,实际仅1例存活超过1年。
- 中位OS为14.5周。
- 零例确认缓解,1例疾病稳定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Metastatic anaplastic thyroid cancer (ATC) has a poor prognosis. This pilot study aims to evaluate tremelimumab plus durvalumab with stereotactic body radiotherapy (SBRT) to improve overall survival (OS). Methods: Eligible patients received up to 4 doses tremelimumab (75 mg) given q4 weeks and up to 1 year of durvalumab (1500 mg) given q4 weeks. SBRT at 9 Gy × 3 fractions was given within the first 2 weeks of the start of treatment. Paired biopsies (pretreatment and between 3 and 10 weeks after the first dose of the drug treatment) were done in the medically qualified patients. Major inclusion criteria are metastatic ATC, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, no prior immunotherapy, and last anticancer treatment >7 days before starting the study. The primary endpoint was 1 year OS with the combination of durvalumab, tremelimumab, and SBRT in metastatic ATC patients with a target of 1 year OS in ≥2 out of 12 patients. Results: A total of 13 patients signed consent but only 12 patients ultimately participated in this trial. One patient who consented to the protocol became ineligible for this study due to continued decline in performance status. Patient characteristics were as follows: male (n = 6) with a median age of 71 years (range: 49-82), and ECOG = 1. Nine patients had prior neck radiation and nine patients had prior chemotherapy. Next-generation sequencing and PD-L1 staining were done in the nine patients where tissue was available. High microsatellite instability (MSI) corresponding to mismatch repair defect was noted in two patients. There were zero confirmed responses and only one patient had stable disease and was treated with ≥4 cycles of study drugs. The median time that the patients were under treatment was 11 weeks (1-28 weeks). MSI status did not affect treatment response. High MSI patients were on treatment for 8-14 weeks before disease progression. The median OS was 14.5 weeks with only 1 patient alive beyond 1 year. The presence of a BRAF or p53 mutation did not appear to affect treatment outcome. Conclusions: Tremelimumab and durvalumab with SBRT did not improve OS for ATC. Future research is needed to examine other novel immunotherapy combinations with or without radiotherapy in the treatment of ATC. Clinical Trial Registration: NCT03122496.
引用
- Lee NY, Riaz N, Wu V, et al. A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. Thyroid. 2022. PMID: 35521657. doi:10.1089/thy.2022.0050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。